EMA Authorised: Avastin (bevacizumab) — Roche Registration GmbH

View source ↗

Summary

The EMA authorised Avastin (bevacizumab) under Roche Registration GmbH for multiple cancer indications. The listed diseases include non-small cell lung cancer, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Colorectal Cancer
• Fallopian Tube Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung;Breast Neoplasms;Ovarian Neoplasms;Colorectal Neoplasms;Carcinoma, Renal Cell;Fallopian Tube Neoplasms;Peritoneal Neoplasms;Uterine Cervical Neoplasms. MAH: Roche Registration GmbH. Decision date: 12/01/2026